Heart scans aim to solve amyloidosis treatment mystery
NCT ID NCT07112066
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why about one-third of people with a heart condition called cardiac amyloidosis continue to get worse even with medication. Researchers will use special heart scans (ultrasound, MRI, and PET) at the start and after one year to see what is happening inside the heart muscle. The goal is to better understand the disease, not to test a new treatment. 50 adults starting a standard drug called tafamidis will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYLOIDOSIS CARDIAC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Zurich
RECRUITINGZurich, Canton of Zurich, 8091, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden heart condition may affect aortic stenosis outcomes – can imaging catch it?
- Heart imaging may reveal hidden clues in rare heart disease
- Hidden heart risk: study aims to catch deadly protein buildup before symptoms start
- New study tracks heart disease progression with Cutting-Edge MRI
- Heart rhythm risks in ATTR amyloidosis patients on tafamidis under scrutiny
- Heart tissue analysis aims to unlock better diagnosis